Ori Biotech
United Kingdom
- London, England
- 18/01/2022
- Series B
- $100,000,000
Ori Biotech is a London- and New Jersey-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalised, lifesaving treatments.
By fully automating and standardising CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing.
So complex manufacturing challenges can be put where they belong – in the past.
- Industry Automation Machinery Manufacturing
- Website https://oribiotech.com/
- LinkedIn https://www.linkedin.com/company/oribiotech-ltd/about/
Related People
Jason C. FosterFounder
United Kingdom -
London, England
Leveraging my commercial expertise and detailed knowledge of the UK, US and EU healthcare markets, I help build organizations that maximize the value of their products & services to improve health and achieve significant returns for investors.
Forage | $40,000,000 | (Jun 5, 2026)
InCharge Energy | $46,000,000 | (Jun 5, 2026)
Oak Hill Bio | $32,500,000 | (Jun 5, 2026)
ZutaCore | $100,000,000 | (Jun 5, 2026)
Terra AI | $20,000,000 | (Jun 5, 2026)
Town | $55,000,000 | (Jun 5, 2026)
Lassie | $35,000,000 | (Jun 5, 2026)
OFFROAD | $7,000,000 | (Jun 5, 2026)
Shifters | $10,200,000 | (Jun 5, 2026)
Quobly | $133,545,475 | (Jun 5, 2026)
Scispot | $8,000,000 | (Jun 5, 2026)
Scotch | $20,000,000 | (Jun 5, 2026)